Posted by: 2019-07-13 05:00:29 , By Admin

9 July 2019 News release Geneva: WHO's Essential Medicines List and List of Essential Diagnostics are core guidance documents that help countries prioritize critical health products that should be widely available and affordable throughout health systems. Published today, the two lists focus on cancer and other global health challenges, with an emphasis on effective solutions, smart prioritization, and optimal access for patients. "Around the world, more than 150 countries use WHO's Essential Medicines List to guide decisions about which medicines represent the best value for money, based on evidence and health impact," said WHO Director-General Dr Tedros Adhanom Ghebreyesus. "The inclusion in this list of some of the newest and most advanced cancer drugs is a strong statement that everyone deserves access to these life-saving medicines, not just those who can afford them." The Essential Medicines List (2019) Cancer treatments: While several new cancer treatments have been marketed in recent years, only a few deliver sufficient therapeutic benefits to be considered essential. The 12 medicines WHO added to the new Medicines List for five cancer therapies are regarded as the best in terms of survival rates to treat melanoma, lung, prostate, multiple myeloma and leukemias cancers. For example, two recently developed immunotherapies (nivolumab and pembrolizumab) have delivered up to 50% survival rates for advanced melanoma, a cancer that until recently was incurable. Antibiotics: The Essential Medicines Committee strengthened advice on antibiotic use by updating the AWARE categories, which indicate which antibiotics to use for the most common and serious infections to achieve better treatment outcomes and reduce the risk of antimicrobial resistance. The committee recommended that three new antibiotics for the treatment of multi-drug resistant infections be added as essential. Other updates to the medicines list include: New oral anticoagulants to prevent stroke as an alternative to warfarin for atrial fibrillation and treatment of deep vein thrombosis. These are particularly advantageous for low-income countries as, unlike warfarin, they do not require regular monitoring; Biologics and their respective biosimilars for chronic inflammatory conditions such as rheumatoid arthritis and inflammatory bowel diseases; Heat-stable carbetocin for the prevention of postpartum haemorrhage. This new formulation has similar effects to oxytocin, the current standard therapy, but offers advantages for tropical countries as it does not require refrigeration; Not all submissions to the EML Committee are included in the list. For example, medicines for multiple sclerosis submitted for inclusion were not listed. The Committee noted that some relevant therapeutic options currently marketed in many countries were not included in the submissions; it will welcome a revised application with all relevant available options. The EML Committee also did not recommend including methylphenidate, a medicine for attention deficit hyperactivity disorder (ADHD), as the committee found uncertainties in the estimates of benefit. The List of Essential (in vitro) Diagnostics The first List of Essential Diagnostics was published in 2018, concentrating on a limited number of priority diseases - HIV, malaria, tuberculosis, and hepatitis. This year's list has expanded to include more noncommunicable and communicable diseases. Cancers: Given how critical it is to secure an early cancer diagnosis (70% of cancer deaths occur in low- and middle-income countries largely because most patients are diagnosed too late), WHO added 12 tests to the Diagnostics List to detect a wide range of solid tumours such as colorectal, liver, cervical, prostate, breast and germ cell cancers, as well as leukemia and lymphomas. To support appropriate cancer diagnosis, a new section covering anatomical pathology testing was added; this service must be made available in specialized laboratories. Infectious diseases: The list focuses on additional infectious diseases prevalent in low- and middle-income countries such as cholera, and neglected diseases like leishmaniasis, schistosomiasis, dengue, and zika. In addition, a new section for influenza testing was added for community health settings where no laboratories are available. General test: The list was also expanded to include additional general tests which address a range of different diseases and conditions, such as iron tests (for anemia), and tests to diagnose thyroid malfunction and sickle cell (an inherited form of anemia very widely present in Sub-Saharan Africa). Another notable update is a new section specific to tests intended for screening of blood donations. This is part of a WHO-wide strategy to make blood transfusions safer. "The List of Essential Diagnostics was introduced in 2018 to guide the supply of tests and improve treatment outcomes," said Mariangela Simao, WHO Assistant Director-General for Medicines and Health Products. "As countries move towards universal health coverage and medicines become more available, it will be crucial to have the right diagnostic tools to ensure appropriate treatment." Note to editors The updated Essential Medicines List adds 28 medicines for adults and 23 for children and specifies new uses for 26 already-listed products, bringing the total to 460 products deemed essential for addressing key public health needs. While this figure may seem high, it corresponds to a fraction of the number of medicines available on the market. By focusing the choices, WHO is emphasizing patient benefits and wise spending with a view to helping countries prioritize and achieve universal health coverage. The updated List of Essential Diagnostics contains 46 general tests that can be used for routine patient care as well as for the detection and diagnosis of a wide array of disease conditions, and 69 tests intended for the detection, diagnosis and monitoring of specific diseases. The List is divided into two sections depending on the user and setting: one for community settings, which includes self-testing; and a second one for clinical laboratories, which can be general and specialized facilities. Both WHO lists are models for countries to develop their own national lists. National lists based on local disease burden and existing healthcare delivery infrastructure provide an excellent framework from which countries can plan and implement the laboratory services and the medicines they need. Access to these health products requires good procurement practices, effective supply chains, quality management protocols and qualified health care workforces. The delivery of effective diagnostic services, because they are based on technologies, also depends on robust technical specifications, the availability of carefully designed laboratory networks, adequate supporting infrastructure and appropriate education of users (patient or health worker) to ensure safety. Corrigendum This news release has been changed to say "The 12 medicines WHO added to the new Medicines List for five cancer therapies are regarded as the best in terms of survival rates to treat melanoma, lung, prostate, multiple myeloma and leukemias cancers." Previous version of this sentence stated the following: "The five cancer therapies WHO added to the new Medicines List are regarded as the best in terms of survival rates to treat melanoma, lung, blood and prostate cancers."

Read more: Click Here

You may like similar news

Responding to a measles outbreak during the COVID-19 pandemic

  2020-07-09 08:08:25

Going village to village, "door to door" and "boat to boat" to maintain routine immunization services - and protect Cambodians from COVID-19 On a sunny day in May, Bun Sreng Sineth and other immunization staff set up an immunization site in a Musl...

Read in detail

Global scientific community unites to track progress on COVID-19 R&D, identifies new research priorities and critical gaps

  2020-07-09 08:00:04

The World Health Organization held a two half-day virtual summit on 1 and 2 July, to take stock of the evolving science on COVID-19 and examine progress made so far in developing effective health tools to improve the global response to the pandemic. ...

Read in detail

WHO calls for more research into microplastics and a crackdown on plastic pollution

  2019-08-23 08:40:26

22 August 2019 / News release / Geneva: The World Health Organization (WHO) today calls for a further assessment of microplastics in the environment and their potential impacts on human health, following the release of an analysis of current researc...

Read in detail

Health benefits far outweigh the costs of meeting climate change goals

  2018-12-08 01:08:01

5 December 2018 News Release Katowice, Poland Meeting the goals of the Paris Agreement could save about a million lives a year worldwide by 2050 through reductions in air pollution alone. The latest estimates from leading experts also indicate that...

Read in detail

Housing impacts health: New WHO Guidelines on Housing and Health

  2018-11-30 02:25:29

Geneva, Switzerland, 27 November 2018 The quality of housing has major implications for people's health. Poor housing is associated with a wide range of health conditions such as respiratory diseases including asthma, cardiovascular diseases, inju...

Read in detail

Read more »

New Jobs

Senior Program Manager - State Projects

  2019-12-02         Delhi

View & Apply

Assistant Manager - Monitoring & Evaluation

  2019-03-29         Maharashtra

View & Apply

Head - Finance & Accounts

  2019-03-29         Karnataka

View & Apply

Center Manager

  2019-03-16         Andhra Pradesh

View & Apply

Project Coordinator

  2019-03-15         Delhi

View & Apply

Senior Manager/ Manager - Health

  2019-03-13         Maharashtra

View & Apply